AR107282A1 - TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP) - Google Patents
TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP)Info
- Publication number
- AR107282A1 AR107282A1 ARP170100004A ARP170100004A AR107282A1 AR 107282 A1 AR107282 A1 AR 107282A1 AR P170100004 A ARP170100004 A AR P170100004A AR P170100004 A ARP170100004 A AR P170100004A AR 107282 A1 AR107282 A1 AR 107282A1
- Authority
- AR
- Argentina
- Prior art keywords
- receiver
- glucagon
- glp
- gip
- peptide
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente solicitud se refiere a un agonista triple que tiene actividades para todos los receptores de glucagón, GLP-1, y GIP y usos de los mismos. Asimismo se refiere a una composición para la prevención o el tratamiento del síndrome metabólico que comprende dichos péptidos.The present application refers to a triple agonist that has activities for all glucagon, GLP-1, and GIP receptors and uses thereof. It also refers to a composition for the prevention or treatment of the metabolic syndrome comprising said peptides.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150191082 | 2015-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR107282A1 true AR107282A1 (en) | 2018-04-18 |
Family
ID=62104015
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100003A AR107281A1 (en) | 2015-12-31 | 2017-01-02 | PROLONGED CONJUGATE OF THE TRIGONAL GLUCAGON RECEIVER AGONIST / GLP-1 / GIP |
ARP170100004A AR107282A1 (en) | 2015-12-31 | 2017-01-02 | TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100003A AR107281A1 (en) | 2015-12-31 | 2017-01-02 | PROLONGED CONJUGATE OF THE TRIGONAL GLUCAGON RECEIVER AGONIST / GLP-1 / GIP |
Country Status (3)
Country | Link |
---|---|
AR (2) | AR107281A1 (en) |
MA (4) | MA42891B2 (en) |
MY (1) | MY199261A (en) |
-
2016
- 2016-12-30 MA MA42891A patent/MA42891B2/en unknown
- 2016-12-30 MY MYPI2018001199A patent/MY199261A/en unknown
- 2016-12-30 MA MA51955A patent/MA51955B1/en unknown
- 2016-12-30 MA MA42889A patent/MA42889B2/en unknown
-
2017
- 2017-01-02 AR ARP170100003A patent/AR107281A1/en unknown
- 2017-01-02 AR ARP170100004A patent/AR107282A1/en unknown
-
2018
- 2018-07-26 MA MA53533A patent/MA53533A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR107281A1 (en) | 2018-04-18 |
MA51955B1 (en) | 2022-04-29 |
MA42891A1 (en) | 2019-04-30 |
MY199261A (en) | 2023-10-23 |
MA53533A1 (en) | 2022-08-31 |
MA42891B2 (en) | 2021-11-30 |
MA42889A1 (en) | 2018-11-30 |
MA51955A1 (en) | 2021-10-29 |
MA42889B2 (en) | 2020-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022000557A1 (en) | Glucagon/glp-1/gip receptor triple agonist (divisional 2 application 202002034) | |
DOP2018000297A (en) | DERIVATIVE OF GLUCAGON, CONJUGATE OF THE SAME, COMPOSITION THAT INCLUDES THE SAME AND THERAPEUTIC USE OF THE SAME | |
CL2019001465A1 (en) | New compounds as trigonal peptide agonists of glp1 / glucagon / gip receptors. | |
CL2017001760A1 (en) | Co-agonist compounds of gip and glp-1 | |
CR20170129A (en) | USE OF A DUAL GLP-1 / GLUCAGON RECEPTOR AGONIST OF LONG-TERM ACTION FOR THE TREATMENT OF NON-ALCOHOLIC FAT LIVER DISEASE | |
PE20180449A1 (en) | DERIVATIVE OF GLUCAGON AND A COMPOSITION THAT INCLUDES A CONJUGATE OF PROLONGED ACTION OF THE SAME | |
AR099977A1 (en) | DOUBLE PEPTIDE AGONISTS OF THE RECIPIENTS OF THE SIMILAR PEPTIDE TO GLUCAGON 1 (GLP-1) AND OF THE GLUCAGON RECEIVER (GCG), DERIVED FROM EXENDINA-4 | |
CL2014003421A1 (en) | Glucagon analogs exhibiting agonist activity at the glusose-dependent insulinotropic peptide receptor (gip): pharmaceutical composition; and method to reduce weight gain or induce weight loss, particularly for the treatment of obesity. | |
AR102712A1 (en) | INSULIN RECEPTOR PARTIAL AGONISTS | |
EP3463429A4 (en) | Insulin receptor partial agonists and glp-1 analogues | |
UY36779A (en) | NEW DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS | |
CL2017001483A1 (en) | Fixed ratio formulation of insulin glargine / lixisenatide | |
PH12018502274A1 (en) | Semaglutide in cardiovascular conditions | |
PH12017501205A1 (en) | Glucagon derivatives | |
AR107282A1 (en) | TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP) | |
CR20190161A (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
AR102978A1 (en) | FORMULATION OF FIXED INSULIN GLARGINE / LIXISENATIDA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |